[JURIST] The US Securities and Exchange Commission [official website] is examining whether investors paid researchers to reveal information about ongoing drug studies in order to profit from the results before they were available to the public. Earlier this month, The Seattle Times [newspaper website] said it found 26 cases [ST report] in which medical researchers "leaked confidential and critical details" to brokerage firms and hedge funds for profit. "The latest revelations have been added to the ongoing review of possible insider trading involving potential blockbuster drugs in advance of FDA decisions," an SEC official said. The FDA will assist the SEC in its investigation under an interagency cooperation agreement. Reuters has more.